Schaefer K, von Herrath D, Erley C M, Asmus G
Medizinische Abteilung II, St. Joseph-Krankenhaus I, Berlin.
Miner Electrolyte Metab. 1990;16(6):362-4.
Since treatment of uremic hyperphosphatemia still represents a major problem and phosphate-binding agents carry the well-known risk of aluminum intoxication, we carried out a study to determine whether calcium ketovaline, a keto acid containing calcium, would show phosphate-binding effects comparable to those obtained with a mixture of amino acids and calcium salts of ketoanalogues tested previously. In vitro as well as in vivo studies show convincingly that calcium ketovaline is a valuable intestinal phosphate binder. Dialysis patients treated for 6 weeks showed a significant (p less than 0.05) decrease in serum phosphate from 2.36 +/- 0.19 to 1.81 +/- 0.16 mmol/l.
由于尿毒症高磷血症的治疗仍然是一个主要问题，且磷结合剂存在众所周知的铝中毒风险，我们开展了一项研究，以确定含酮戊二酸钙的酮酸——酮戊二酸钙是否会显示出与先前测试的氨基酸和酮类似物钙盐混合物相当的磷结合效果。体外和体内研究均令人信服地表明，酮戊二酸钙是一种有价值的肠道磷结合剂。接受治疗6周的透析患者血清磷从2.36±0.19显著降低至1.81±0.16mmol/L（p＜0.05）。
